| Preoperative oral care and effect on postoperative complications after major cancer surgery M Ishimaru, H Matsui, S Ono, Y Hagiwara, K Morita, H Yasunaga Journal of British Surgery 105 (12), 1688-1696, 2018 | 95 | 2018 |
| REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients K Shitara, T Yamanaka, T Denda, Y Tsuji, K Shinozaki, Y Komatsu, ... Annals of Oncology 30 (2), 259-265, 2019 | 67 | 2019 |
| Impact of resection and ablation for single hypovascular hepatocellular carcinoma≤ 2 cm analysed with propensity score weighting K Takayasu, S Arii, M Sakamoto, Y Matsuyama, M Kudo, S Kaneko, ... Liver International 38 (3), 484-493, 2018 | 33 | 2018 |
| Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III … T Shiroiwa, T Fukuda, K Shimozuma, M Mouri, Y Hagiwara, H Doihara, ... Quality of Life Research 26, 445-453, 2017 | 30 | 2017 |
| Impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer: results from the … Y Hagiwara, T Shiroiwa, K Shimozuma, T Kawahara, Y Uemura, ... Pharmacoeconomics 36, 215-223, 2018 | 27 | 2018 |
| Prevalence, incidence rate, and risk factors of medication-related osteonecrosis of the jaw in patients with osteoporosis and cancer: a nationwide population-based study in Japan M Ishimaru, S Ono, K Morita, H Matsui, Y Hagiwara, H Yasunaga Journal of Oral and Maxillofacial Surgery 80 (4), 714-727, 2022 | 21 | 2022 |
| Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer Y Hagiwara, T Shiroiwa, N Taira, T Kawahara, K Konomura, S Noto, ... Health and quality of life outcomes 18 (1), 1-10, 2020 | 20 | 2020 |
| Prognostic impact of sustained new-onset atrial fibrillation in critically ill patients T Yoshida, S Uchino, Y Sasabuchi, Y Hagiwara Intensive Care Medicine 46, 27-35, 2020 | 19 | 2020 |
| Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01) Y Hagiwara, Y Ohashi, K Uesaka, N Boku, A Fukutomi, Y Okamura, ... European Journal of Cancer 93, 79-88, 2018 | 17 | 2018 |
| Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with … H Yamaue, A Shimizu, Y Hagiwara, M Sho, H Yanagimoto, S Nakamori, ... Cancer chemotherapy and pharmacology 79, 813-823, 2017 | 16 | 2017 |
| Effect of diameter and number of hepatocellular carcinomas on survival after resection, transarterial chemoembolization, and ablation Y Kawaguchi, K Hasegawa, Y Hagiwara, M De Bellis, S Famularo, ... Official journal of the American College of Gastroenterology| ACG 116 (8 …, 2021 | 15 | 2021 |
| Sodium‐glucose cotransporter‐2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative … Y Takeuchi, H Kumamaru, Y Hagiwara, H Matsui, H Yasunaga, H Miyata, ... Diabetes, Obesity and Metabolism 23 (6), 1379-1388, 2021 | 14 | 2021 |
| Impact of body weight gain on the incidence of nonalcoholic fatty liver disease in nonobese Japanese individuals G Yamada, Y Hagiwara, T Kimura, Y Takeuchi, K Oba, K Masuda, ... Official journal of the American College of Gastroenterology| ACG 116 (4 …, 2021 | 13 | 2021 |
| Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer … Y Hagiwara, Y Ohashi, T Okusaka, H Ueno, T Ioka, N Boku, S Egawa, ... ESMO open 2 (1), e000151, 2017 | 13 | 2017 |
| Patient-reported outcome results from the open-label randomized phase iii select bc trial evaluating first-line s-1 therapy for metastatic breast cancer T Kawahara, K Shimozuma, T Shiroiwa, Y Hagiwara, Y Uemura, ... Oncology 94 (2), 107-115, 2018 | 10 | 2018 |
| REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with … Y Tsuji, K Shitara, T Yamanaka, T Denda, K Shinozaki, Y Komatsu, ... Journal of Clinical Oncology 36 (15_suppl), 3510-3510, 2018 | 7 | 2018 |
| Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial Y Hagiwara, M Sawaki, Y Uemura, T Kawahara, K Shimozuma, Y Ohashi, ... Breast Cancer Research and Treatment 188 (3), 675-683, 2021 | 5 | 2021 |
| The number of events per confounder for valid estimation of risk difference using modified least-squares regression Y Hagiwara, M Fukuda, Y Matsuyama American Journal of Epidemiology 187 (11), 2481-2490, 2018 | 5 | 2018 |
| Diagnostic ability using fatty liver and metabolic markers for metabolic‐associated fatty liver disease stratified by metabolic/glycemic abnormalities A Okada, G Yamada, T Kimura, Y Hagiwara, S Yamaguchi, KI Kurakawa, ... Journal of Diabetes Investigation 14 (3), 463-478, 2023 | 4 | 2023 |
| Simultaneous relaxometry and morphometry of human brain structures with 3D magnetic resonance fingerprinting: a multicenter, multiplatform, multifield-strength study S Fujita, M Cencini, G Buonincontri, N Takei, RF Schulte, I Fukunaga, ... Cerebral Cortex 33 (3), 729-739, 2023 | 4 | 2023 |
